COVID-19, which was first reported in December 2019 in China, has caused a global outbreak. Five variants of concern (VOCs) have been identified in different countries since the global pandemic, namely, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.529). Although multiple vaccines have been found to be effective, some of the amino acid changes may increase the infectivity of virus and decrease the sensitivity to antibodies. Here we characterize the VOCs and discuss their sensitivity to antibodies elicited by convalescent and vaccinee sera. In conclusion, several variants display a reduction in the susceptibility to neutralization antibodies generated by natural infection or vaccination, which threatens the containment of the epidemic.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Gorbalenya AE, Baker SC, Baric RS et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5(4), 536–544 (2020).
MedlineGoogle Scholar
2. Wu F, Zhao S, Yu B et al. A new coronavirus associated with human respiratory disease in China. Nature 579(7798), 265–269 (2020).
Medline CASGoogle Scholar
3. Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270–273 (2020).
Medline CASGoogle Scholar
4. Sevajol M, Subissi L, Decroly E, Canard B, Imbert I. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Res. 194, 90–99 (2014).
Medline CASGoogle Scholar
5. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 9(8), e1003565 (2013).
Medline CASGoogle Scholar
6. Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 16(8), e3000003 (2018).
MedlineGoogle Scholar
7. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 6(7), e1001005 (2010).
MedlineGoogle Scholar
8. Sehra ST, Salciccioli JD, Wiebe DJ, Fundin S, Baker JF. Maximum daily temperature, precipitation, ultraviolet light, and rates of transmission of severe acute respiratory syndrome coronavirus 2 in the United States. Clin. Infect. Dis. 71(9), 2482–2487 (2020).
Medline CASGoogle Scholar
9. Rambaut A, Loman N, Pybuset O et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological (2020). https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-SARS-CoV-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563
Google Scholar
10. Tegally H, Wilkinson E, Giovanetti M et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv doi: https://doi.org/10.1101/2020.12.21.20248640 (2020) (Epub ahead of print).
Google Scholar
11. Faria N, Claro IM, Candido D et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in manaus: preliminary findings. Virological (2021). https://virological.org/t/genomic-characterisation-of-an-emergent-SARS-CoV-2-lineage-in-manaus-preliminary-findings/586
Google Scholar
12. World Health Organization. Tracking SARS-CoV-2 variants (2021). https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ • Information of new SARS-CoV-2 variants could be traced from the WHO website.
Google Scholar
13. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2 Transcriptome. Cell 181(4), 914–921 (2020).
Medline CASGoogle Scholar
14. Yao H, Song Y, Chen Y et al. Molecular Architecture of the SARS-CoV-2 Virus. Cell 183(3), 730–738 (2020).
Medline CASGoogle Scholar
15. Lai MMC, Perlman S, Anderson LJ. Coronaviridae. In Fields Virology (5th Edition). Knipe DMHowley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 1306–1335 (2007).
Google Scholar
16. Wang Q, Zhang Y, Wu L et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181(4), 894–904 (2020).
Medline CASGoogle Scholar
17. Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum. Vaccin. Immunother. 16(6), 1239–1242 (2020).
Medline CASGoogle Scholar
18. Yuan M, Wu NC, Zhu X et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368(6491), 630–633 (2020).
Medline CASGoogle Scholar
19. Chi XY, Yan RH, Zhang J et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369(6504), 650–655 (2020). •• It described the neutralization activity of 4A8 and pointed that antibodies-targeting N-terminal domain (NTD) may also important to the preventation or therapeutic of SARS-CoV-2.
Medline CASGoogle Scholar
20. Wang P, Nair MS, Liu L et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593(7857), 130–135 (2021). • It reported the reduced susceptibility of Alpha and Beta to antibodies against the receptor-binding domain and N-terminal domain. In addition, it pointed out that Beta may be more worrisome when compared with Alpha.
Medline CASGoogle Scholar
21. Amanat F, Thapa M, Lei T et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184(15), 3936–3948 (2021).
Medline CASGoogle Scholar
22. Tang XC, Agnihothram SS, Jiao Y et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl Acad. Sci. USA 111(19), 2018–2026 (2014).
Medline CASGoogle Scholar
23. Sui J, Aird DR, Tamin A et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 4(11), e1000197 (2008).
MedlineGoogle Scholar
24. terMeulen J, van den Brink EN, Poon LL et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3(7), e237 (2006).
MedlineGoogle Scholar
25. Korber B, Fischer WM, Gnanakaran S et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182(4), 812–827 (2020). •• It reported the emergence of D614G variant and pointed that it increased the transmissibility of SARS-CoV-2.
Medline CASGoogle Scholar
26. Lorenzo-Redondo R, Nam HH, Roberts SC et al. A unique clade of SARS-CoV-2 viruses is associated with lower viral loads in patient upper airways. medRxiv doi: 10.1101/2020.05.19.20107144 (2020) (Epub ahead of print).
MedlineGoogle Scholar
27. Wagner C, Roychoudhury P, Hadfield J et al. Comparing viral load and clinical outcomes in Washington State across D 614G mutation in Spike protein of SARS-CoV-2 (2020). https://github.com/blab/ncov-wa-d614g/blob/39f87ba09a8e9ad1789052039f8602a445364b9e/README.md
Google Scholar
28. Zhang L, Jackson CB, Mou H et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11(1), 6013 (2020).
Medline CASGoogle Scholar
29. Daniloski Z, Jordan TX, Ilmain JK et al. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. Elife 10, e65365 (2021).
Medline CASGoogle Scholar
30. Ozono S, Zhang Y, Ode H et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun. 12(1), 848 (2021).
Medline CASGoogle Scholar
31. Tada T, Dcosta BM, Samanovic-Golden M et al. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv doi: 10.1101/2021.02.05.430003 (2021).
Google Scholar
32. Baric RS. Emergence of a Highly Fit SARS-CoV-2 Variant. N. Engl. J. Med. 383(27), 2684–2686 (2020).
Medline CASGoogle Scholar
33. Wang GL, Wang ZY, Duan LJ et al. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N. Engl. J. Med. 384(24), 2354–2356 (2021).
Medline CASGoogle Scholar
34. Public Health England. Investigation of novel SARS-CoV-2 variant. variant of concern 202012/01: technical briefing. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959360/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3.pdf
Google Scholar
35. Davies NG, Abbott S, Barnard RC et al. Estimated transmissibility and severity of novel SARS-CoV-2 variant of concern 202012/01 in England. medRxiv doi: https://doi.org/10.1101/2020.12.24.20248822 (2021) (Epub ahead of print).
Google Scholar
36. Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. bioRxiv doi: 10.1101/2021.02.22.432359 (2021) (Epub ahead of print).
Google Scholar
37. Gu H, Chen Q, Yang G et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369(6511), 1603–1607 (2020).
Medline CASGoogle Scholar
38. Starr TN, Greaney AJ, Hilton SK et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182(5), 1295–1310 (2020).
Medline CASGoogle Scholar
39. Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 Is essential for infection of human lung cells. Mol. Cell 78(4), 779–784 (2020).
Medline CASGoogle Scholar
40. Peacock TP, Goldhill DH, Zhou J, Baillon L, Barclay WS. The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells. bioRxiv doi: https://doi.org/10.1101/2020.09.30.318311 (2020) (Epub ahead of print).
Google Scholar
41. Kemp SA, Collier DA, Datir R et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv doi: https://doi.org/10.1101/2020.12.05.20241927 (2020) (Epub ahead of print).
MedlineGoogle Scholar
42. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 372, n579 (2021).
MedlineGoogle Scholar
43. Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593(7858), 270–274 (2021). • It is the first article which reported the Alpha variant causes increasing mortality.
Medline CASGoogle Scholar
44. Lan J, Ge J, Yu J et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581(7807), 215–220 (2020).
Medline CASGoogle Scholar
45. Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc. Natl Acad. Sci. USA 117(25), 13967–13974 (2020).
Medline CASGoogle Scholar
46. Pearson CAB, Russell TW, Davies N et al. Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa. Centre for Mathematical Modelling of Infectious Diseases (2021). https://cmmid.github.io/topics/covid19/sa-novel-variant.html
Google Scholar
47. Naveca F, Nascimento V, Souza V et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in spike protein. Virological (2021). https://virological.org/t/phylogenetic-relationship-of-SARS-CoV-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585
Google Scholar
48. Yao W, Wang Y, Ma D et al. Circulating SARS-CoV-2 variants B.1.1.7, 501Y.V2, and P.1 have gained ability to utilize rat and mouse Ace2 and altered in vitro sensitivity to neutralizing antibodies and ACE2-Ig. bioRxiv doi: https://doi.org/10.1101/2021.01.27.428353 (2021) (Epub ahead of print).
Google Scholar
49. Chen J, Wang R, Wang M, Wei GW. Mutations Strengthened SARS-CoV-2 Infectivity. J. Mol. Biol. 432(19), 5212–5226 (2020).
Medline CASGoogle Scholar
50. Tchesnokova V, Kulakesara H, Larson L et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants. bioRxiv doi: https://doi.org/10.1101/2021.02.22.432189 (2021) (Epub ahead of print).
MedlineGoogle Scholar
51. Greaney AJ, Loes AN, Crawford KHD et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29(3), 463–476 (2021).
Medline CASGoogle Scholar
52. Li Q, Wu J, Nie J et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182(5), 1284–1294 (2020).
Medline CASGoogle Scholar
53. Li B, Deng A, Li K et al. Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. medRxiv doi: https://doi.org/10.1101/2021.07.07.21260122 (2021) (Epub ahead of print).
Google Scholar
54. Nchioua R, Schundner A, Klute S et al. The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells. bioRxiv doi: https://doi.org/10.1101/2021.11.16.468777 (2021) (Epub ahead of print).
Google Scholar
55. Kuhlmann C, Mayer CK, Claassen M et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 399(10325), 625–6263 (2022).
Medline CASGoogle Scholar
56. Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384(5), 403–416 (2021).
Medline CASGoogle Scholar
57. Polack FP, Thomas SJ, Kitchin N et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383(27), 2603–2615 (2020).
Medline CASGoogle Scholar
58. Gao Q, Bao L, Mao H et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369(6499), 77–81 (2020).
Medline CASGoogle Scholar
59. Wang H, Zhang Y, Huang B et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182(3), 713–721 (2020).
Medline CASGoogle Scholar
60. Xia S, Zhang Y, Wang Y et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 21(1), 39–51 (2021).
Medline CASGoogle Scholar
61. Logunov DY, Dolzhikova IV, Shcheblyakov DV et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397(10275), 671–681 (2021). •• It reported the effectiveness of heterologous prime-boost COVID-19 vaccines.
Medline CASGoogle Scholar
62. Voysey M, Clemens SAC, Madhi SA et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269), 99–111 (2021).
Medline CASGoogle Scholar
63. Wu S, Zhong G, Zhang J et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11(1), 4081 (2020).
Medline CASGoogle Scholar
64. Wang C, Liu Z, Chen Z et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J. Med. Virol. 92(6), 667–674 (2020).
Medline CASGoogle Scholar
65. Marot S, Malet I, Jary A et al. Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. bioRxiv doi: https://doi.org/10.1101/2021.03.05.434089 (2021) (Epub ahead of print).
Google Scholar
66. Planas D, Bruel T, Grzelak L et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27(5), 917–924 (2021).
Medline CASGoogle Scholar
67. Shen X, Tang H, McDanal C et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29(4), 529–539 (2021).
Medline CASGoogle Scholar
68. Edara VV, Floyd K, Lai L et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv doi: https://doi.org/10.1101/2021.02.02.21250799 (2021) (Epub ahead of print).
Google Scholar
69. Muik A, Wallisch AK, Sänger B et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science 371(6534), 1152–1153 (2021).
Medline CASGoogle Scholar
70. Wu K, Werner AP, Moliva JI et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv doi: https://doi.org/10.1101/2021.01.25.427948 (2021) (Epub ahead of print).
Google Scholar
71. Callaway E, Mallapaty S. Novavax covid vaccine protects people against variants. Nature 590(7844), 17 (2021).
Medline CASGoogle Scholar
72. Edara VV, Norwood C, Floyd K et al. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant. bioRxiv doi: https://doi.org/10.1101/2021.02.20.432046 (2021) (Epub ahead of print).
Google Scholar
73. Wang WB, Liang Y, Jin YQ, Zhang J, Su JG, Li QM. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: binding free energy calculation studies. bioRxiv doi: https://doi.org/10.1101/2021.02.17.431566 (2021) (Epub ahead of print).
Google Scholar
74. Wang P, Wang M, Yu J et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv doi: https://doi.org/10.1101/2021.03.01.433466 (2021) (Epub ahead of print).
Google Scholar
75. Liu Z, VanBlargan LA, Bloyet LM et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29(3), 477–488 (2021).
Medline CASGoogle Scholar
76. Palacios R, Batista AP, Albuquerque CSN et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. http://dx.doi.org/10.2139/ssrn.3822780 (2021).
Google Scholar
77. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect. 28(2), 202–221 (2021).
MedlineGoogle Scholar
78. Lopez Bernal J, Andrews N, Gower C et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385(7), 585–594 (2021). • Found that both BNT162b2 and ChAdOx1vaccines were less effective against the delta variant than against the B.1.1.7 (Alpha) variant.
MedlineGoogle Scholar
79. Tada T, Zhou H, Samanovic M et al. Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. bioRxiv doi: https://doi.org/10.1101/2021.07.19.452771 (2021) (Epub ahead of print).
Google Scholar
80. Edara VV, Pinsky BA, Suthar MS et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N. Engl. J. Med. 385(7), 664–666 (2021). •• It reported that the circulating Delta variant was less susceptible to the serum from convalescent and two mRNA vaccinees.
MedlineGoogle Scholar
81. Liu C, Ginn HM, Dejnirattisai W et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184(16), 4220–4236 (2021).
Medline CASGoogle Scholar
82. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N. Engl. J. Med. 386(5), 494–496 (2021).
MedlineGoogle Scholar
83. Cameroni E, Saliba C, Bowen JE et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv doi: https://doi.org/10.1101/2021.12.12.472269 (2021) (Epub ahead of print).
Google Scholar
84. Doria-Rose NA, Shen X, Schmidt SD et al. Booster of mRNA-1273 strengthens SARS-CoV-2 omicron neutralization. medRxiv doi: https://doi.org/10.1101/2021.12.15.21267805 (2021) (Epub ahead of print).
Google Scholar
85. Levin EG, Lustig Y, Cohen C et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 385(24), e84 (2021).
Medline CASGoogle Scholar
86. Robert L, Atmar KE, Lyke ME et al. Heterologous SARS-CoV-2 booster vaccinations – preliminary report. medRxiv doi: https://doi.org/10.1101/2021.10.10.21264827 (2021) (Epub ahead of print).
Google Scholar
87. Ho TC, Chen YA, Chan HP et al. The effects of heterologous immunization with prime-boost COVID-19 vaccination against SARS-CoV-2. Vaccines (Basel) 9(10), 1163 (2021).
Medline CASGoogle Scholar
88. Garcia-Beltran WF, Lam EC, St Denis K et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184(9), 2372–2383 (2021).
Medline CASGoogle Scholar
89. Madhi SA, Baillie V, Cutland CL et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384(20), 1885–1898 (2021).
Medline CASGoogle Scholar
90. Emary KRW, Golubchik T, Aley PK et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 397(10282), 1351–1362 (2021).
Medline CASGoogle Scholar
91. Kandikattu HK, Yadavalli CS, Venkateshaiah SU, Mishra A. Vaccine efficacy in mutant SARS-CoV-2 variants. Int. J. Cell. Biol. Physiol. 4(1–2), 1–12 (2021).
MedlineGoogle Scholar

Vol. 17, No. 6

Metrics

Downloaded 519 times

History

Received 26 April 2021

Accepted 18 March 2022

Published online 26 April 2022

Published in print June 2022

Information

Keywords

Financial & competing interests disclosure

Beijing DCTY® Biotech Co., Ltd. funded the editing. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

English language editing was done by Enago.

PDF download